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Erythropoiesis is arranged in erythroblastic islands (Ery-Is) [1] , the specialized niche known for >50 years [2] in which erythroid precursors proliferate and differentiate, but its significance for anemia, the leading symptom of myelodysplastic syndromes (MDS), is unclear up to now. Evaluating bone marrow biopsies (BMBs) from patients with MDS, we detected alterations of Ery-Is in a significant proportion of patients independently associated with severe anemia and poor prognosis of disease -a novel observation.
We evaluated the diagnostic BMBs from a total of 317 patients with MDS newly diagnosed according to the French-American-British classification [3] , monitored and treated by best supportive care in more than 20 hematology centers (RARS, n=36; RA, n=109; RAEB, n=82; RAEB/t, n=40; CMML, n=50);
WHO classification [4] : RARS, n=11; RCUD, n=32; MDS with isolated del(5q), n=19; MDS U, n=3;
RCMD, n=66; RAEB-1, n=37; RAEB-2, n=37; CMML-1, n=34; CMML-2, n=27; RARS-T / MDS/MPN U, n=18; AML with MDS-related changes, n=14; therapy-related MDS, n=19. 52 persons with normal healthy marrow served as a control group (see: "supplementary information").
Ery-Is are composed of a central macrophage surrounded by and binding to nucleated erythroid cells (NEC) [5, 6] . Normoblasts were marked using anti-hemoglobin-A (HbA), HbA -NEC using antiglycophorin-C and -CD71 antibodies (details: "supplementary information"). To overcome difficulties in separating confluencing or adjacent Ery-Is (supplementary Table 2 ), size and numerical density of Ery-Is were determined indirectly by a statistical approach. Each biopsy section was divided into 20
areas "A" of equal size, and each area into 100 adjacent virtual squares "sq" of 30.5 µm², each comprising ~10 nucleated cells (measuring oculars), amounting to a total count of ~20 000 nucleated cells per biopsy section. Squares with ≥50% NEC were determined as "sq+". Each A served as a block with similar proportions of marrow zones (proliferation / differentiation zones) to eliminate their possible influence (block design). Numerical density and size of Ery-Is were determined by analysis of variance components [7] assuming that differences in the sq+ counts between A result from clustering of NEC Table 2 ).
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Since the interaction between macrophage and NEC appears to be essential for the differentiation of erythropoiesis [1, 5, 8, 9] . Ery-Is were also evaluated as to the existence of a central macrophage marked by anti-CD68 (PGM1 [10] , all cases) and anti-CD169 antibody (10% of cases, details: "supplementary information").
Healthy marrow differed significantly from MDS in all the alterations of erythropoesis (supplementary Table 3 ). Whereas impaired maturation of erythropoiesis, dysplastic features in >10% of NEC and apoptosis in >1% of NEC were not observed in healthy marrow, they occurred in 92.0%, 60.3% and 49.5% of MDS patients. Differences with respect to Ery-Is were less obvious at first sight since Ery-Is were detectable in MDS as well as in healthy marrow ( Figure 1 A-F), and in healthy marrow, Ery-Is changed significantly with a person's age: in persons older than 60 years, their numerical density progressively declined accompanied by a progressive increase in their size (P<0.0005, Figures 1 C,F, 2
A-B), alterations resembling those observed in MDS. Senescence, an increased risk of clonal hematopoiesis in normal elderly individuals with mutations similar to those observed in MDS [11, 12] , or aging of the hematopoietic stem cell niche [13, 14] might be an explanation. In MDS, however, the alterations of Ery-Is did not depend on the age of patients (Table 1 , Figure 1 C,F; P>0.05). They significantly exceeded that observed in aging healthy marrow and were associated with progressive anemia (P<0.000005; Table 1 ), whereas the alterations of Ery-Is in aging healthy marrow were not associated with anemia (all persons with healthy marrow showed normal Hb values) or changes in Hb value of peripheral blood (P>0.1). These differences to healthy marrow were independent of the sex and age of patients (Table 1 , Figure 1 A-F).
The Ery-Is in patients with >15% ring sideroblasts within erythropoiesis, a loss of the Y chromosome, or >1% apoptotic NEC were significantly larger than in other MDS patients ( Impaired formation resulting in reduced numbers of Ery-Is showed the most significant influence on the Hb level of blood contributing to 20-25% of the degree of anemia independently of all other alterations of erythropoiesis (P<0.00001; Table 1 ). It was the only alteration of erythropoiesis predicting the risk of (progressive) red blood cell (RBC) transfusion dependence independently of the type of disease, the risk group (IPSS-R) [15] , and the occurrence of MF ( Figure 1 G; Table 1 ) -a further novel observation. Hematopathologic evaluations of BMBs in MDS patients should therefore include a statement on the numerical density of Ery-Is within marrow, especially in cases with a marked reduction of this entity.
In summary, Ery-Is appear to be significantly altered in many patients with MDS, and these alterations seem to play a central role in the evolution of severe transfusion-dependent anemia in this type of disease. Background may be a differentiation defect at the level of an early erythroid precursor cell, responsible for the production of Ery-Is, and / or an impaired interaction between macrophages and NEC [8] , thus impairing the formation of Ery-Is as suggested by our observation of a dissociation of macrophages from a small proportion (≥10%) of Ery-Is in the majority of patients.
Impaired formation of Ery-Is may be the only pathologic change of erythropoiesis in a minority of patients with MDS. In the majority, the numerical density of Ery-Is seems to be normal or increased, and 
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Title and legend of -0.010 ± 0.001 P < 0.00001 dissociation of macrophages from ≥ 10% of Ery-Is -0.148 ± 0.027 P < 0.00001 n.s. impaired maturation of erythropoiesis 0.145 ± 0.039 P = 0.00001 n.s. apoptosis >1 % of NEC 0.142 ± 0.044 P = 0.0006 +4.7 ± 2.0 P < 0.00001 numerical density of Ery-Is within marrow: log(Ery-Is / mm³) -6.1 ± 0.5 P < 0.00001 RARS, RCMD-RS, RARS-T n.s. +17.6 ± 3.1 P < 0. one RBC transfusion per month in patients who were transfusion independent on the day of diagnosis of MDS or increase in transfusion dependence by ≥ one RBC transfusion per month in patients who were transfusion dependent on the day of diagnosis of MDS; 3 the subtypes "MDS U" (AML-free survival, risk of tansfusion-dependent anemia) and "AML with MDSrelated changes" (risk of tansfusion-dependent anemia) served as reference category(-ies). 4 Cases not classified according to IPSS-R served as reference category.
5 MF0 (no fibrosis) served as reference category. 3 -5 Each category of the predictor variables except the reference categories were compared to the overall effect. In MDS, the numerical density of Ery-Is within marrow was significantly lower than in healthy bone marrow (A -C) whereas the Ery-Is were enlarged (D -F; P < 0.000001). These differences were independent of the sex of patients (A, B, D, E; P > 0.05).
In healthy marrow, numerical density and size of Ery-Is changed significantly with the age of a person (C, F; P < 0.001; blue lines) whereas the alterations observed in MDS were independent of the age of patients (red lines; P > 0.05; C, F). In healthy marrow as well as in MDS, the size of Ery-Is (mean diameter) correlated inversely with their numerical density within marrow (P < 0.000001). The risk of transfusion-dependent anemia and the (AML-free) survival time of patients significantly depended on the numerical density of Ery-Is within bone marrow (G, H; P < 0.00002). 
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Supplementary information: Inclusion criteria of the patients with MDS:
This group comprised a total of 317 patients with MDS monitored and treated in more than 20 hematology centers all over Germany who fulfilled the following inclusion criteria:
(1) All patients had been admitted to the hematology center within the last two decades because of an unclear cytopenia without any history of a life-threatening bone marrow disease, 298 of them without any history of a neoplastic disorder, radiation or chemotherapy. 19 patients who had been cured of a neoplastic disorder by radiation or chemotherapy at least 5 years earlier without any history of a relapse or a neoplastic involvement of bone marrow, who showed normal peripheral blood findings for more than four years and did not receive any further radiation or chemotherapy after cure of this neoplasia, were included as "therapy-related MDS".
(2) Their bone marrow had been aspirated and biopsied with informed consent by colleagues using
BMBs as a standard in the diagnosis of any unclear cytopenia, planning up-front for every patient to have aspirate and biopsy for initial diagnosis of the cause of unclear cytopenia, sending all the BMBs from their patients with cytopenia(s) to our hematopathology department, and (3) aspirating the bone marrow from all patients with a myeloid neoplasm for cytogenetic evaluation. 
no evidence of a disorder of bone marrow on the day when the BMB was taken and for a follow-up period of six months after taking the BMB (6) no evidence of another systemic or neoplastic disease in the past and for a follow-up period of up to six months after taking the BMB, and (7) no history of radiation or chemotherapy.
Cytogenetic investigations:
Cytogenetic analyses were performed according to standard procedures [1] . Samples providing less than 10 metaphases were excluded. When the bone marrow of a patient was aspirated twice within two months before or after diagnosis of disease with a total number of 10 or more metaphases in both samples, the cytogenetic data from both samples were considered and handled as a single analysis.
Description of chromosome aberrations and clone definition followed the recommendations of the International System for Cytogenetic Nomenclature (ISCN) [1] . A complex karyotype was defined as ≥3 aberrations within one clone.
Morphologic evaluation:
From all BMBs, 3 µm thin sections were stained using Maywald-Giemsa, Prussian blue, and Gomori silver impregnation. All cell lines were evaluated for dysplastic features as proposed by the WHO classification (nuclear atypias, dysplastic features of cytoplasms, such as hypogranulation of granulocytes, cytoplasmic PAS positivity of NEC etc., as well as altered ratio of nucleus to cytoplasm of cells). For each cell line, dysplastic features were registered when exceeding 10 % of nucleated cells. Diseases IV were classified according to the criteria of the FAB group and the World Health Organization (WHO) [2, 3] by two experts, a hematologist (bone marrow aspirates) and a hematopathologist (BMBs) or by two hematopathologists. Controversial cases were discussed to come to a final consensus of diagnosis and classification. Three cases which remained controversial were classified as "MDS U".
Monocytes, promonocytes, and monoblasts were marked by anti-CD68 (PGM1) antibody [4, 5] . The antibody PGM1 applied is highly sensitive (100 %) with respect to the identification of macrophages, and we have not as yet observed any patient with MDS whose macrophages were PGM1-negative. This antibody marks a subset of CD68 found on macrophages, monocytic cells (monocytes, promonocytes, monoblasts), plasmocytoid dendritic cells, histiocytic sarcoma and neoplastic mast cells (mastocytosis, mast cell leukemia), but it does not mark other hematopoietic cells, such as granulocytes, nor other lymphatic (B-or T-) cells as observed with other CD68 antibodies [4] .
Abnormal localization of immature precursor cells (ALIP) were defined as clusters or aggregates of ≥ 3 blasts located outside the proliferation zone of granulopoiesis. A case was registered as ALIP-positive when at least three ALIP clusters or aggregates were detected within a BMB section. CD34 and CD117 immunophenotyping were applied to facilitate the detection of ALIPs and blasts and to determine the blast content in controversial cases. Marrow fibrosis (MF) was diagnosed as proposed by the WHO and as described earlier [6, 7] . Hypoplasia was diagnosed in cases with a marked reduction in marrow cellularity to a value not observed in age-related cases with healthy marrow.
Any reduction in the number of clusters of ≥5 adjacent NEC to values lower than the 5% percentile observed in healthy marrow was termed "impaired formation of Ery-Is". Cases with reduced numbers of clusters with ≥5 adjacent NEC, but with loose aggregates of non-adjacent NEC or small goups with <5
NEC without a central macrophage, were called "disruption of Ery-Is", cases with reduced numbers of Ery-Is, but without loose aggregates or small goups of NEC, were described as "loss of Ery-Is".
Erythropoiesis was furthermore evaluated for impaired maturation, apoptotic NEC, and Ery-Is. Apoptosis was scored visually whether or not affecting > 1% of erythroid precursor cells. Pyknotic nuclei in terminal normoblasts were excluded from apoptosis counts. Any shift in the proportion of terminal normoblasts to immature erythroblasts and / or proerythroblasts compared to the findings in normal healthy marrow was described as "impaired maturation". Among cases with an impaired maturation, two groups were distinguished, those with versus without megaloblastoid changes of NEC.
The association of macrophages with Ery-Is was checked indirectly by comparing the counts of PGM1 + macrophages [4, 5] sectioned through their nucleus and detected within an Ery-I (serial sections V alternatively stained with anti-PGM1 and anti-CD71 or double staining of anti-CD71 with anti-PGM1 or anti-CD169) with the estimated numbers of Ery-Is cut through their center within a tissue section. A relevant dissociation was diagnosed when the counts of Ery-I-associated macrophages fell below 90 % of the estimated numbers of Ery-I centers.
Ery-Is, macrophages, erythroid apoptosis, cellularity, ALIP, and MF were analyzed by evaluating BMBs, and ring sideroblasts by evaluating bone marrow aspirates. All the other morphologic evaluations were done by evaluating both bone marrow aspirates and BMBs. Ery-Is, erythroid apoptosis, impaired maturation of erythropoiesis, percentage of ring sideroblasts, marrow cellularity, evidence of ALIP and MF were evaluated by a single investigator. The results on Ery-Is were controlled by a second investigator who was blinded to the results from the first investigator by re-evaluating the BMBs from 214 (exact approach) and 51 (manual counts) randomly selected cases.
Immunohistochemistry:
The following antibodies were applied to mark various hematopoietic cells antibody against purchased from: dilution: applied to mark the following cell type: 
CD34
Statistical analyses:
The chi-square test, analysis of variance, the Mann-Whitney U test, uni-and multivariate variance components models, linear and Poisson regression analyses were used to test for differences and correlations. Log-rank test and Cox proportional hazards regression analysis were used to test for the prognostic significance of variables. A result was regarded as "significant" if the probability P of the null hypothesis was <0.05.
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The contribution of a variable to the degree of anemia was checked by analysis of variance components. The variance component attributable to a variable was estimated by the Methods of Moments.
Each variance component was presented as the percentage of the variation of anemia which was estimated as the total variance of the Hb value of peripheral blood minus the normal variation of Hb value (which was determined by the variance of the Hb value of peripheral blood in the control group). 2 5-29% blasts in the differential count (peripheral blood) or 20-29% blasts in the bone marrow; cases classified as "RAEB/t" according to the FAB classification were classified as "RAEB-2", "AML", or "CMML-2" in the WHO classification.
Supplementary
3 peripheral blood blasts > 19% or white blood cell count > 12 * 10 9 / L or neutrophils > 8 * 10 9 / L or the peripheral blood cell counts were not stable for ≥ 2 months. 4 ± another (not complex) chromosome aberration; cases may also appear in another cytogenetic group. 5 < 30% blasts in blood and bone marrow with MDS of the residual hematopoiesis. 6 patients with history of radiation of chemotherapy, but without history of a neoplastic disease of bone marrow and without evidence of a neoplastic disease other than MDS on the day of diagnosis of MDS. 7 patients with MDS U, CMML, RARS-T, AML, or therapy-related MDS erythropoiesis: impaired maturation -1.662 ± 0.193 P < 0.000001 -2.580 ± 0.178 P < 0.000001 dysplastic features ≥ 10 % of NEC -1.820 ± 0.285 P < 0.000001 -3.564 ± 0.317 P < 0.000001 apoptosis >1% of NEC -1.491 ± 0.296 P = 0.000001 -3.291 ± 0.353 P < 0.000001 Ery-Is size (diameter) [* 20 µm] -0.039 ± 0.006 P < 0.000001 -0.059 ± 0.006 P < 0.000001 numerical density [log(Ery-Is / mm³)]
1.170 ± 0.138 P < 0.000001 1.568 ± 0.118 P < 0.000001 Ery-Is: dissociation of macrophages -1.153 ± 0.168 P < 0.000001 -2.165 ± 0.180 P < 0.000001 1 not tested because of too few cases; 2 ± other chromosome aberration(s) 1 ≥ one RBC transfusion per month in patients transfusion independent on the day of diagnosis or increase in transfusion dependence by ≥ one RBC transfusion per month in transfusion-dependent patients; 2 the subtypes "MDS U" (AML-free survival , risk of tansfusiondependent anemia) and "AML with MDS-related changes" (risk of tansfusion-dependent anemia) served as reference category(-ies).
3 significant in multivariate analysis. 4 Cases not classified served as reference category. 5 ± other chromosome aberration(s); 6 not tested because of too few cases.
